They concluded that there are prominent metabolic differences between in vitro tumor cells and primary human tumor tissue that must be taken into account when developing precise therapeutic strategies for homozygous MTAP‐deficient glioblastomas [16]. This evidence concerns the gene MTAP and glioblastoma.